Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 Shares

Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $38.49, for a total transaction of $384,900.00. Following the transaction, the senior vice president now owns 168,176 shares in the company, valued at approximately $6,473,094.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO opened at $37.81 on Friday. The firm has a fifty day moving average price of $39.50 and a 200-day moving average price of $37.76. The company has a debt-to-equity ratio of 17.89, a current ratio of 6.64 and a quick ratio of 5.50. The stock has a market cap of $4.80 billion, a PE ratio of 17.92, a price-to-earnings-growth ratio of 0.46 and a beta of 1.25. Halozyme Therapeutics, Inc. has a 1 year low of $29.85 and a 1 year high of $45.00.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The firm had revenue of $230.04 million during the quarter, compared to analysts’ expectations of $235.25 million. Halozyme Therapeutics had a return on equity of 248.20% and a net margin of 33.96%. Equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Benchmark restated a “buy” rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Tuesday. TD Cowen assumed coverage on shares of Halozyme Therapeutics in a research report on Thursday, February 29th. They set an “outperform” rating and a $54.00 price objective on the stock. The Goldman Sachs Group lowered their price objective on shares of Halozyme Therapeutics from $45.00 to $40.00 and set a “neutral” rating on the stock in a research report on Thursday, January 18th. JMP Securities reiterated a “market outperform” rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, February 21st. Finally, Morgan Stanley decreased their price target on shares of Halozyme Therapeutics from $61.00 to $59.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 26th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $53.29.

Institutional Trading of Halozyme Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Advisors Asset Management Inc. grew its stake in Halozyme Therapeutics by 0.6% during the third quarter. Advisors Asset Management Inc. now owns 45,598 shares of the biopharmaceutical company’s stock valued at $1,742,000 after acquiring an additional 287 shares in the last quarter. First Horizon Advisors Inc. grew its stake in Halozyme Therapeutics by 24.5% during the fourth quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after acquiring an additional 293 shares in the last quarter. Advisory Services Network LLC grew its stake in Halozyme Therapeutics by 50.5% during the first quarter. Advisory Services Network LLC now owns 903 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 303 shares in the last quarter. Fifth Third Bancorp grew its stake in Halozyme Therapeutics by 2.6% during the third quarter. Fifth Third Bancorp now owns 12,262 shares of the biopharmaceutical company’s stock valued at $468,000 after acquiring an additional 308 shares in the last quarter. Finally, Prudential Financial Inc. grew its stake in Halozyme Therapeutics by 1.5% during the first quarter. Prudential Financial Inc. now owns 22,540 shares of the biopharmaceutical company’s stock valued at $1,003,000 after acquiring an additional 336 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.